HUGO-Ab™ Humanized Antibody Mouse Models

Driven by the demand for innovative fully human antibody drug development, Cyagen has leveraged its strong capabilities in technological innovation and its proprietary TurboKnockout^® ES targeting technology to develop the next-generation HUGO-Ab^TM(HUmanized Genomic Ortholog for Antibody development) fully human antibody mice. These models carry the complete set of human immunoglobulin genes and are capable of producing fully human antibodies in vivo with high affinity and low immunogenicity.

The HUGO-Ab^TM fully human antibody mouse series includes:

• HUGO-Mab™: Fully human monoclonal antibody mice 
• HUGO-Light™: Fully human common light chain antibody mice 
• HUGO-Nano™: Fully human heavy chain only antibody mice

These models offer extensive antibody sequence diversity, encompassing all human antibody heavy chains, as well as kappa and lambda light chain variable region germline genes. Their exceptional performance has proven effective in antibody discovery, earning recognition from multiple multinational pharmaceutical companies, biotech companies, and academic institutions. As such, they serve as a powerful engine for the development of novel therapeutic antibodies.

Building upon the HUGO-Ab^TM platform, Cyagen has launched the comprehensive HUGO-Ab-eKO™ Homology Knockout Express Program, which enables rapid, efficient, and personalized customization services. We warmly invite researchers worldwide to collaborate and accelerate the development of therapeutic antibody drugs.

Advantages of HUGO-Ab^TM Humanized Antibody Mouse Models

• Comprehensive Series of Human Antibody Mouse Products
  
  Includes HUGO-Mab™ mice, HUGO-Light™ mice, HUGO-Nano™ mice, and HUGO-Ab-eKO™ mice. Available on C57BL/6, BALB/c, and SJL genetic backgrounds.
  
  
• Fully Independent Intellectual Property
  
  Developed using Cyagen’s proprietary TurboKnockout^® ES targeting technology, which enables megabase-scale gene knock-in and knockout. This approach ensures precise, in situ gene replacement with no off-target effects, high stability, and clear IP ownership—making it a preferred gene editing solution for new drug development projects.
  
  
• Fully Humanized Antibody Development
  
  Carries human-derived genes for antibody heavy chains and both kappa and lambda light chain variable regions. The inclusion of humanized Lambda germline genes enhances antibody diversity and more closely mimics the diversity found in natural human antibodies.
  
  
• Fully Enhanced Immune Response Capability
  
  The HUGO-Ab-eKO™ mice, based on the HUGO-Ab^TM platform, achieve knockout of endogenous mouse genes for highly homologous targets. This enhances the immune response, increasing the success rate of antibody screening and making it easier to obtain high-affinity, high-specificity, and cross-reactive antibody candidates.
  
  
• One-Time Fee Commercial Model
  
  Available for licensing or co-development with a one-time payment model.

AbSeek™ Intelligent Antibody Computing Platform

AbSeek™ is an intelligent computing platform specifically designed for antibody discovery and engineering. It integrates cutting-edge artificial intelligence with advanced bioinformatics technologies and is equipped with both proprietary and open-source computational and visualization modules, delivering outstanding speed and accuracy.

The AbSeek™ platform comprehensively supports all stages of antibody development—from screening to optimization and validation—by offering a suite of tools for antibody sequence analysis, structural and functional prediction, lead compound optimization, and antibody molecule generation. It streamlines and automates the antibody design workflow, accelerating efficient innovation in the field of antibody engineering.